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Blockade of Death Receptor-Mediated Pathways
Early in the Signaling Cascade Coincides with Distinct
Apoptosis Resistance in Cutaneous T-Cell Lymphoma
Cells
Frank K. Braun1, Lothar F. Fecker1, Constanze Schwarz1, Peter Walden1, Chalid Assaf1, Horst Du¨rkop2,
Wolfram Sterry1 and Ju¨rgen Eberle1
Control of apoptosis via death ligands plays a basic role for lymphocyte homeostasis and lymphoma
development. In this study, cutaneous T-cell lymphoma (CTCL) cell lines revealed pronounced resistance to
death ligands as compared to cell lines of T-cell acute lymphoblastic leukemia (T-ALL). The proapoptotic activity
of tumor necrosis factor (TNF)-a was blocked, sensitivity to TNF-related apoptosis-inducing ligand was
significantly reduced, and 1/4 CTCL cell lines was resistant to CD95 activation. In parallel, there was no activation
of effector caspase-3 and initiator caspase-8 in nonresponsive CTCL cells, whereas caspase-10 was cleaved
selectively in sensitive CTCL cells. No indication for a responsibility of typical downstream regulators of
apoptosis was obtained, but loss of CD95 was found in 1/4, loss of TNF-R1 in 3/4, loss of caspase-10 in 2/4, loss of
Bid in 1/4, and overexpression of cellular flice inhibitory protein was found in 4/4 CTCL cell lines. This clearly
indicates an inhibition of apoptosis early in the extrinsic cascade, namely at the formation of the death-inducing
signaling complex. Parallels with regard to expression of apoptosis regulators were seen in peripheral blood
mononuclear cells and biopsies of CTCL patients. This study may indicate defects in apoptosis in CTCL and may
help to guide CTCL therapy.
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INTRODUCTION
Incidence of non-Hodgkin lymphoma (NHL) ranges between
10 and 20/100,000 in most Western countries and has been
increasing within the last decades. About 5% of NHL show a
primary cutaneous manifestation. Whereas systemic lympho-
mas are predominantly of B-cell type, in the skin, T-cell
lymphomas are about three times more frequent than B-cell
lymphomas (Groves et al., 2000; Muller et al., 2005;
Willemze et al., 2005). Among the systemic T-cell lympho-
mas, T-cell acute lymphoblastic leukemia (T-ALL) constitutes
approximately 25% of all adult cases of ALL (Bassan et al.,
2004).
Cutaneous T-cell lymphoma (CTCL) are a clinically and
biologically distinct group of NHL defined by clonal
proliferation of skin-homing malignant T-lymphocytes with-
out evidence for systemic disease at the time of first diagnosis.
In clinical appearance and prognosis, they are clearly
different from the histotypically cognate systemic lymphomas
and their possible secondary cutaneous manifestations
(Willemze et al., 2005). Typically, they have the immuno-
phenotype of CD3þ CD4þ CD45ROþ memory T-lympho-
cytes. Their distinct characteristics have been recently
acknowledged by the new WHO/EORTC classification (Burg
et al., 2005). The most common forms are mycosis fungoides
(MF), Se´zary syndrome, and CD30þ lymphoproliferative
disorders. The molecular mechanisms involved in the
pathogenesis of CTCL, however, are still far from understood.
Programmed cell death (apoptosis) is a fundamental
mechanism for controlling cellular homeostasis. In the
defense against cancer, it serves as an efficient safeguard
mechanism that eliminates mutated or virus-infected cells
that may bear the capacity to develop cancer. Two major
apoptosis pathways lead to an ordered destruction of cellular
components while membrane integrity is maintained (Reed,
2004). The extrinsic pathway is initiated by death ligands that
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typically employ the proapoptotic caspase cascade (Lavrik
et al., 2005). In contrast, the classical intrinsic pathway
depends on mitochondrial release of proapoptotic factors
such as cytochrome c and subsequent activation of initiator
caspase-9 (Riedl and Shi, 2004). This step is critically
regulated by the family of Bcl-2-related proteins such as
Bcl-2, Bax, Bak, and Bid.
The family of extrinsic death ligands includes tumor
necrosis factor (TNF)-a, CD95/Fas ligand, and TNF-related
apoptosis-inducing ligand (TRAIL), which can bind to their
respective death receptors TNF-R1, CD95, TRAIL-R1/DR4,
and TRAIL-R2/DR5 or to decoy receptors such as TRAIL-R3/
DcR-1 or TRAIL-R4/DcR-2. The downstream signaling
cascade involves receptor oligomerization, formation of the
death-inducing signaling complex (DISC) by enclosing the
adaptor protein FADD, activation of initiator caspases-8 or
-10, activation of effector caspases, cleavage of death
substrates, and finally DNA fragmentation (Wang and El
Deiry, 2003; Lavrik et al., 2005). In parallel, death ligands
may also trigger pathways that lead to activation of NF-kB or
mitogen-activated protein kinases (Di Pietro and Zauli,
2004).
The control of apoptosis via death ligands and receptors is
of special significance for lymphocyte homeostasis. Lympho-
cyte precursors are produced in excess and the vast majority
are destined to be early eliminated. Similarly, immune
responses are to be terminated when the antigen is gone.
Both mechanisms involve extrinsic signaling particularly
though the CD95 system. The critical role of the extrinsic
pathways for lymphocyte homeostasis is illustrated by mouse
mutants or human syndromes where death ligands or
receptors are defective and lymphocytic hyperproliferation
is the outcome (Li-Weber and Krammer, 2003). Interrupting
extrinsic apoptosis pathways, thus, seems to be of special
importance for the development of lymphomas.
Cell culture models provide first and general approaches
to collect clues on the characteristics of a given tumor, which
then need to be proven in more subsequent clinical studies.
Here, we investigated the sensitivity of CTCL cell lines to
death ligands and found a significantly increased resistance
to apoptosis as compared to T-ALL cell lines. To determine
the basis of this resistance, we investigated the respective
signaling pathways and the expression of critical apoptosis
regulators. This led to a comprehensive characterization of
apoptosis control in CTCL cells.
RESULTS
Reduced sensitivity of CTCL cells for extrinsic proapoptotic
signals
For better understanding of apoptosis regulation in cutaneous
lymphoma, we investigated the sensitivity of four CTCL cell
lines (HH, HuT-78, MyLa, and SeAx) to the death ligands
TRAIL and TNF-a as well as to the agonistic CD95 antibody
CH-11. The sensitivity was compared to that of four T-ALL
cell lines (Jurkat, MOLT-4, CCRF-CEM, and Karpas-45).
Seven of eight cell lines revealed pronounced sensitivity to
agonistic stimulation of CD95. Only the cutaneous lym-
phoma cell line SeAx was completely resistant to CH-11
(100 ng/ml). All T-ALL cell lines responded with significant
increase of apoptosis to treatment with TNF-a (10 ng/ml); in
contrast, there was no apoptotic response in any of the
CTCL cell lines. Furthermore, the apoptotic response of all
CTCL cell lines to TRAIL treatment (20 ng/ml) was strongly
reduced with an in average 1.8-fold increase 70.5, as
compared to the T-ALL cell lines with 4.1-fold increase71.9.
Thus, apoptosis sensitivity of CTCL cell lines to death ligands
is largely reduced or even blocked (Figure 1).
Activation of the caspase cascade on extrinsic stimulation
correlates with sensitivity
To obtain insights into signal pathways activated in CTCL
cells on extrinsic stimulation of death receptors, the cell lines
were investigated for activation of caspase-8, the main
initiator caspase of extrinsic pathways, for degradation of
Bid, which represents the bridge between extrinsic and
mitochondrial pathway, for caspase-9, the initiator caspase
downstream of the mitochondria as well as for activation of
the main effector caspase-3. Corresponding with their
sensitivity, caspase-8, -9, and -3 became activated in the
T-ALL cells after treatment with TNF-a, TRAIL, and CH-11,
whereas caspases were activated only on CH-11 treatment in
three CTCL cell lines that were sensitive to CD95-mediated
apoptosis (Figure 2). In contrast, cleavage of Bid was only
seen after treatment with CH-11 in one T-ALL cell line (Jurkat)
and two CTCL cell lines (HuT-78 and MyLa). The other two
CTCL cell lines were either nonresponsive (SeAx) or did not
show any Bid expression (HH). In particular, the Bid-
mediated pathway was not activated in 3/4 T-ALL cell lines
despite their high sensitivity to death ligands. These data
clearly indicated that extrinsic death signals triggered
activation of the caspase cascade in sensitive cells and that
apoptosis was blocked in the CTCL cells at an early step
before activation of caspase-8.
Partial lack of death receptors in CTCL cell lines
To investigate whether the reduced sensitivity of the CTCL
cells was the result of altered expression of receptors, FACS
analyses were performed for the two agonistic TRAIL
receptors (DR4 and DR5) and two TRAIL decoy receptors
(DcR1, DcR2) as well as for CD95. In addition, Western blot
analysis was performed for DR4 and DR5 and for TNF-R1, the
death receptor of TNF-a.
Significant surface expression of DR4 and DR5 was seen
in almost all cell lines with the exceptions of DR4 in the
cell lines MyLa and MOLT-4 as well as DR5 in Karpas-45
(Figure 3a and b). Expression of TRAIL receptors was not
correlated with TRAIL sensitivity, as all CTCL cell lines were
characterized by high expression of at least one of the TRAIL
receptors. In most CTCL cell lines, death receptor expression
was even higher than in the T-ALL cells (Figure 3d). Surface
expression of TRAIL decoy receptors (DcR1 and DcR2) was
only weak in all eight lymphoma cell lines investigated as
compared to controls HeLa and SW480. However, some
expression of both receptors was seen in the CTCL cell line
SeAx, which may have contributed to its reduced sensitivity
to TRAIL (Figure 4).
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A result comparable with the FACS data was seen for
agonistic TRAIL receptors when total protein extracts were
analyzed by Western blotting: high DR4 expression (44 kDa)
(Kurbanov et al., 2005) was characteristic for HuT-78, MyLa,
and SeAx and high expression of DR5 (40/47 kDa) was
characteristic for HuT-78, MyLa, and HH (Figure 5a). Some
deviations between FACS and the Western blot analyses may
be owing to different cellular transport and turnover.
Surface expression of CD95 was high in 3/4 CTCL cell
lines as compared to T-ALL cells but was completely lost in
SeAx (Figure 3c and d). Thus, loss of receptor expression may
be responsible for CD95 resistance of SeAx.
Finally, Western blot analysis for TNF-R1 revealed its lack
in 3/4 cutaneous cell lines (HH, MyLa, and SeAx), whereas it
was strongly expressed in all T-ALL cell lines (Figure 5a). Thus,
also the lack of apoptosis response to TNF-a in three cell lines
may result from death receptor loss, whereas the insensitivity
of HuT-78 seemed to be regulated at a different level.
Variant employment of initiator caspases in CTCL and T-ALL
cells
The caspase cascade is critical for extrinsic activation of
apoptosis. High levels of the main effector caspase-3 were
found both in CTCL and in T-ALL cells and high expression of
caspase-8 was seen in HH, HuT-78, and MyLa, whereas SeAx
and all T-ALL cell lines showed weaker basic levels of
caspase-8. Also, no downregulation of the adapter protein
FADD and caspase-9 was seen in CTCL cells. In contrast,
caspase-10 was lost in the CTCL cell lines HH and SeAx and
Bid showed weak expression in 3/4 CTCL cell lines as
compared to T-ALL cells and was lost in the fourth CTCL cell
line HH (Figures 2 and 5).
Whereas caspase-8 was activated in all apoptosis-
responsive cell lines (Figure 2), activation of caspase-10
was limited to the two CTCL cell lines MyLa and HuT-78
treated with CH-11. No caspase-10 cleavage products were
seen in any of the T-ALL cell lines despite their high
sensitivity to extrinsic signals (Figure 6).
Bcl-2 proteins and inhibitors of apoptosis
The caspase cascade can be blocked at several levels
including inhibition of caspase-8 or -10 by cellular flice
inhibitory protein (c-FLIP), inhibition of downstream caspases
by IAP proteins, inhibition of the mitochondrial pathway by
overexpression of antiapoptotic Bcl-2 proteins or loss of
proapoptotic Bcl-2 proteins.
CTCL cell lines were characterized by strong expression of
Bax, reduced expression of Bcl-2 (3 cell lines), equally strong
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Figure 1. Reduced sensitivity of CTCL cell lines to death ligands. Four CTCL cell lines (HH, HuT-78, MyLa, and SeAx) and four T-ALL cell lines (Jurkat, CCRF-
CEM, MOLT-4, and Karpas-45) were treated for 16 hours with death agonists TNF-a (10 ng/ml), TRAIL (20 ng/ml), and agonistic anti-CD95 antibody CH-11
(100 ng/ml). After incubation, relative DNA fragmentation rates indicative for apoptosis were determined and were calculated as relative values according to
untreated controls (white bars). Mean values7SD of at least two independent experiments each performed with double or triple values are shown. A Po0.05,
as determined by Students t-test, is indicated by *, a Po0.005 is indicated by **.
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expression of survivin, and somewhat weaker expression of
X-linked inhibitor of apoptosis (XIAP), always compared
to T-ALL cells. Thus, these factors may be excluded from
being responsible for the higher apoptosis resistance of
CTCL cells compared to T-ALL cells. Bcl-xL was expressed
strongly only in HuT-78 where it may contribute to
its apoptosis resistance, not, however, in other cell lines
(Figure 7a and b).
The clearest difference was found for the expression of
c-FLIP. Strong FLIPL and FLIPS expression was characteristic
for the four CTCL cell lines, whereas its expression in the
T-ALL cells was much weaker (Figure 7c).
Correlation to the situation in CTCL patients
To address the question whether CTCL cells in vivo may
reveal parallels in their apoptosis regulation to CTCL cell
lines, the expression of c-FLIP, caspase-10, and TNF-R1 was
investigated in peripheral blood mononuclear cell (PBMC)
preparations of Se´zary patients by Western blot analysis. In
addition, expression of c-FLIP was investigated by immuno-
histology in sections of 35 MF biopsies from different tumor
stages (IB, IIB, and III).
Concordant with the findings in CTCL cell lines,
white blood cell samples of Se´zary patients showed
weak expression of TNF-R1 (4/4). However, complicating
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Figure 2. Cleavage of caspases and Bid in apoptosis-sensitive cells. Cleavage of caspase-8, -3, and -9 as well as degradation of Bid were analyzed by Western
blot analysis after stimulation of (a) CTCL and (b) T-ALL lymphoma cell lines for 16 hours with death agonists TNF-a (10 ng/ml), TRAIL (20 ng/ml) and CH-11
agonistic antibody (100 ng/ml). Molecular weights of caspase-8 proforms (53 and 55 kDa) and cleavage products (18, 41, and 43 kDa), of caspase-3 cleavage
products (15, 17, and 20 kDa), of caspase-9 proform (45 kDa) and cleavage product (37 kDa), and of Bid proform (18 kDa) are indicated. Equal amounts of
protein (20 mg per lane) were loaded. Consistent blotting was confirmed by Ponceau red staining and by glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), b-actin, or a-tubulin expression. As expression of Bid was only weak in MyLa, a long exposure time for chemiluminescence detection was used here
as well as for HH. Two experiments performed for each cell line starting from independent cultures yielded very similar results.
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Figure 3. High expression of CD95 and TRAIL receptors in CTCL cells. Surface expression of death receptors (DR4, DR5, and CD95) was determined by flow
cytometry for the CTCL and T-ALL cell lines. The cells were stained with (a) specific monoclonal TRAIL-R1/DR4, (b) TRAIL-R2/DR5, and (c) CD95-specific
antibody (filled graphs). Isotype control antibodies were used as negative controls (open graphs). A shift to the right indicates increased surface expression.
(d) Median expression values obtained for the individual cell lines (each two independent experiments) were normalized with respect to the mean expression in
all eight cell lines. (+) indicates the loss of CD95 expression in SeAx.
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the findings, weak expression of TNF-R1 was also
characteristic for most PBMC preparations of normal blood
donors. Caspase-10 showed reduced expression in 2/4
samples of Se´zary patients but also in half of the
control samples, when compared with T-ALL cell lines
(Figure 8a and b).
Three of four white blood cell samples of the Se´zary
patients showed expression of FLIPL, but no expression of
FLIPS as in the CTCL cell lines (Figure 8a). For comparison,
three of six PBMC samples of healthy donors were also
positive for FLIPL (Figure 8b). Possibly remarkable, the Se´zary
syndrome patient without c-FLIP expression had received the
most pretreatments (psoralenþUVA treatment/IFN-a, metho-
trexate, chlorambucil/prednisolone, extracorporeal photo-
chemotherapy, and leukapheresis).
Immunohistology revealed c-FLIP positivity in all of 35 MF
biopsies with 20–80% positive cells within the tumor lesions
(median positivity: 60%; Figure 8c). Although there is no
specific, reliable molecular marker or technique allowing
clear-cut distinction between tumor cells and infiltrating
lymphocytes, most of the infiltrate in MF is assumed to consist
of tumor cells. This may especially apply to later stages and to
Pautrier microabscesses, of which we show one in Figure 8.
In general, all tumor samples were controlled by routine CD3
and Giemsa staining. When comparing different stages of MF
patients, expression of c-FLIP was higher in stage IB (70%) as
compared to stages IIB/III (40%; Mann–Whitney U test:
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Figure 4. Weak expression of TRAIL decoy receptors in CTCL cells. Surface expression of TRAIL decoy receptors (DcR1 and DcR2) was determined by flow
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Po0.04). This may correlate with a significant role of c-FLIP
especially in an early stage of MF.
DISCUSSION
Tumor growth may occur when apoptosis pathways, nor-
mally efficient safeguard mechanisms in multicellular organ-
isms, are impaired. As extrinsic death receptor-mediated
pathways are basic for lymphocyte homeostasis, they require
special consideration in lymphoma cells. A leading role of
CD95 is well described for selection of maturating lympho-
cytes as well as in activation-induced cell death, which
is involved in downregulation of an immune response
(Krammer, 2000; Li-Weber and Krammer, 2003). But TNF-a
and TRAIL also play their parts hereby.
TNF-a, on one hand supports stimulation of an immune
response via NF-kB activation, to which both TNF receptors
(R1 and R2) may contribute. On the other hand, TNF-R1 may
also trigger apoptosis via its death domain. Proapoptotic
functions of TNF-a with regard to immune downregulation
have been found both in CD8þ and CD4þ T cells (Gupta
et al., 2005). For TRAIL, an involvement in activation-
induced cell death has been reported for CD4þ Th2 helper
cells that express TRAIL after activation (Zhang et al., 2003b)
and for CD8þ T lymphocytes depleted of CD4þ helper cells
(Janssen et al., 2005).
Because of the crucial role of death ligands and receptors
in regulating immune responses, it was challenging to
investigate the accessibility of extrinsic apoptosis pathways
in CTCL cells. This was done in comparison to T-ALL cell
lines that represent a histotypically cognate counterpart of
systemic T-cell lymphomas (Bassan et al., 2004). Whereas all
T-ALL cell lines were sensitive to death ligands, the sensitivity
of CTCL cells was substantially reduced. They revealed
complete resistance to TNF-a-induced apoptosis, reduced
sensitivity to TRAIL, and one cell line showed resistance to
CD95 activation. As most anticancer drugs ultimately aim at
triggering apoptosis pathways (Reed and Pellecchia, 2005),
the present cell culture data may have some meaning for the
high therapy resistance of CTCL in the clinic (Guitart, 2006).
Reduced sensitivity to CD95L has been described for
several tumor entities of hematopoetic origin (Mathas et al.,
2004; Peter et al., 2005; Oyarzo et al., 2006). Resistance to
TNF-a was previously reported for the cell line HuT-78
(Dobbeling et al., 1998; Giri and Aggarwal, 1998) and
resistance to TRAIL was reported for several non-Hodgkin
T-cell lymphoma cell lines including HH (Snell et al., 1997).
SeAx has been reported previously as responsive to TNF-a
with regard to reduced cell survival after long-term treatment
(Dobbeling et al., 1998), but this effect can not be due to an
early induction of apoptosis as we have shown here. With the
larger number of cell lines investigated here, the present data
may indicate that reduced apoptosis sensitivity to TNF-a and
TRAIL is a general characteristic of CTCL cell lines, maybe
related to their possible origin as memory T cells (Burg et al.,
2005).
With regard to the death-promoting signaling cascade
initiated by death ligands, previous studies have emphasized
the major role of caspases in lymphocytic cells (Krammer,
2000). Two initiator caspases (8 and 10) can be activated by
extrinsic stimulation to exert overlapping but also deviating
functions (Fischer et al., 2006). Particularly and in contrast to
caspase-8, we found activation of caspase-10 in CTCL cells
but not in T-ALL cells, possibly indicating its special
significance in these cells. In this context, it may be important
to note that caspase-8 may also contribute to NF-kB
activation and, thereby, lymphocyte activation, whereas
caspase-10 functions seem to be more restricted to apoptosis
(Wang et al., 1999; Chun et al., 2002; Su et al., 2005).
As to possible causes of the apoptosis resistance, the
analysis of the caspase cascade was clearly indicative of an
apoptosis block at an early step. This was concluded from the
finding that the initiator caspases were not activated in the
nonresponsive cells. Correspondingly, there was no indica-
tion of a contribution of typical downstream regulators of
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shown for CTCL cell lines (HH, HuT-78, MyLa, SeAx) and for T-ALL cell lines
(Jurkat, CCRF-CEM, MOLT-4, Karpas-45). Molecular weights are indicated as
44 (DR4), 47/40 (DR5), 55 (TNF-R1), 30 (caspase-3), 55/53 (caspase-8),
60/55 (caspase-10), 25 (FADD), 18 (Bid), 45 (caspase-9), 50 (a-tubulin), and
37 kDa (glyceraldehyde-3-phosphate dehydrogenase). Identical protein
amounts (25 mg per lane) had been loaded to each lane. Consistent blotting
was confirmed by Ponceau red staining and evaluation of a-tubulin or
GAPDH expression. Expression of Bid in MyLa cells was not detectable here
as short exposure times were used for chemiluminescence detection to avoid
signal saturation in other cell lines. However, weak expression of Bid can be
seen in MyLa after longer exposure, as shown in Figure 2, whereas HH
remained negative. Two experiments performed for each cell line starting
from independent cultures revealed reproducible results.
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apoptosis as determined for several representatives of the Bcl-
2 and IAP protein families. Only loss of Bid in 1/4 CTCL cell
lines and its weak expression in the other three CTCL cell
lines was indicative for a limited capability to activate the
mitochondrial pathway by death ligands. Expression of Bcl-2-
related proteins in CTCL cells (Bcl-2, Bax, and Bcl-xL) has
been reported (Dummer et al., 1995; Zhang et al., 2003a).
The regulation of downstream steps in the apoptosis cascade
may therefore be less critical for the resistance of CTCL cells
to death ligands. Factors of the death-inducing signaling
complex (receptors, initiator caspases, and regulating pro-
teins) appeared as the main players.
Loss or weak expression of death receptors may provide a
principle explanation for resistance, as the pathway cannot
be initiated. This could be the cause for lacking apoptosis
after activation of CD95 in the cell line SeAx as well as for
TNF-a resistance in three CTCL cell lines. In clear contrast,
T-ALL cells strongly expressed TNF-R1 and all were
apoptosis-sensitive to TNF-a stimulation. Loss and inactivat-
ing mutations of CD95 have been frequently found in tumors
(Li-Weber and Krammer, 2003) and were also reported for
cutaneous lymphomas (Dereure et al., 2000, 2002; Zoi-Toli
et al., 2000; van Doorn et al., 2002; Nagasawa et al., 2004).
However, weak expression of TNF-R1 has not been described
as a possible mechanism of apoptosis resistance in lymphoma
cells. The correlation of weak TNF-R1 expression and TNF-a
insensitivity, found here in 3/4 cell lines, may suggest a new
mechanism of apoptosis resistance in CTCL cells and
resistance to the proapoptotic functions of TNF-a seems to
be a critical feature of CTCL cells.
No correlation was seen between TRAIL resistance and
receptor expression indicative for a block of TRAIL-initiated
pathways downstream of the receptor. Selective inactivation
of one of the two initiator caspases has been reported for
tumors. This includes loss of caspase-8 expression in small
cell lung carcinoma (Hopkins-Donaldson et al., 2003) and of
caspase-10 in breast carcinomas (Kischkel et al., 2001). Also
for NHL, inactivating mutations of caspase-10 were identified
indicating its significant role in apoptosis regulation (Shin
et al., 2002). In this study, we found loss of caspase-10 in two
CTCL cell lines, whereas expression of caspase-8 was even
stronger than in the T-ALL cells. This corresponds to the
strong caspase-10 activation seen in the two other CTCL cell
lines. Its loss may have a significant antiapoptotic effect in
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Figure 7. High FLIPS/L expression in CTCL cell lines. Expression of the
(a) Bcl-2-related proteins Bax, Bcl-2, Bcl-xL, (b) inhibitor of apoptosis proteins
XIAP and survivin, and (c) FLIPL/S is shown by Western blot analyses of
the CTCL and T-ALL cell lines. Molecular weights were determined as
19 (Bax), 25 (Bcl-2), 29 (Bcl-xL), 55 (XIAP), 17 (survivin), 50 (FLIPL), 23 (FLIPS),
and 50 kDa (a-tubulin). Identity of the 29 kDa band of Bcl-xL has been proven
by a protein extract of a Bcl-xL-overexpressing cell clone, which was loaded
into the corresponding control lane. Identical protein amounts (25 mg per
lane) had been loaded in each lane and consistent blotting was confirmed
by Ponceau red staining and detection of a-tubulin. Two experiments
performed for each cell line starting from independent cultures produced very
similar results.
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CTCL cells, whereas its loss would not block apoptosis in
T-ALL cells where it was not activated.
The competitive inhibitor of both initiator caspases,
c-FLIP, provides an additional way for tumor cells to escape
from death ligand-mediated apoptosis (Dutton et al., 2006).
Its critical role in the resistance to CD95-mediated apoptosis
has been described for Hodgkin lymphoma (Mathas et al.,
2004) and for anaplastic large-cell lymphoma (Oyarzo et al.,
2006). A comparable overexpression of FLIPL and FLIPS is
described here also for CTCL cells, closing the list of
antiapoptotic changes influencing death-inducing signaling
complex functionality. Elevated c-FLIP may depend on
NF-kB activity as shown in Hodgkin–Reed–Sternberg cells
(Mathas et al., 2004) and, correspondingly, high constitutive
NF-kB activity has recently been reported for CTCL cells
(Sors et al., 2006).
Investigation of cell culture models for CTCL provides
early evidence for understanding apoptosis regulation in
CTCL. These data may supply clues for identification of the
right targets in subsequent, clinically related studies. Indeed,
some indications for parallels were already found in CTCL
tumor samples. Further relations may be seen between the
characteristics of the CTCL cell lines and present therapeutic
concepts for CTCL. This may become of special significance,
as apoptosis-based therapies are becoming of increasing
interest for hematological malignancies (Reed and Pellec-
chia, 2005). At first, death ligands are crucial in the self-
control of the immune system and the restoration of TRAIL or
TNF sensitivity may support intrinsic antitumor safeguard
mechanisms against CTCL. Furthermore, the use of death
ligands in antitumor therapy has been tempting. In contrast to
agonistic CD95 antibodies, which caused liver injury and to
TNF-a, which resulted in increased proinflammatory activ-
ities (Ogasawara et al., 1993; Ashkenazi, 2002), TRAIL was
shown to exert its antitumor effects in animal models without
obvious signs of systemic toxicity (Walczak et al., 1999;
Shankar et al., 2005a). Clinical trials have already been
initiated in patients with advanced solid or hematological
tumors (Pukac et al., 2005). However, several systemic NHL
cell lines were resistant to TRAIL-induced apoptosis (Snell
et al., 1997; MacFarlane et al., 2002) as reported here also for
CTCL cells.
TRAIL resistance may be overcome by combination with
other treatments. This has been shown for histone deacetylase
inhibitors such as suberoylanilide hydroxamic acid (SAHA),
which enhanced TRAIL sensitivity in several malignant cells
as shown for breast cancer, prostate cancer, and lymphoma
(Inoue et al., 2004; Butler et al., 2006; Lakshmikanthan et al.,
2006). In lymphoma cells, this effect was related to
upregulation of death receptors and proapoptotic Bcl-2
proteins as well as to downregulation of inhibitors of
apoptosis such as c-FLIP (Shankar et al., 2005b). SAHA is
currently in phase I and II clinical trials for the treatment of
different types of cancer including cutaneous lymphoma. Its
proapoptotic activity has already been demonstrated in CTCL
cells (Zhang et al., 2005). The present findings on the
resistance of CTCL cell lines to TRAIL may be related with the
described effects of SAHA.
Also, proteasome inhibitors such as bortezomib are in
clinical development for myeloma, NHL, and solid tumors
(Richardson et al., 2006). One of their predominant activities
is inhibition of NF-kB, which is a main promoter of c-FLIP
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Figure 8. Expression of c-FLIP in CTCL tumor cells. (a) Expression of caspase-10 (60/55 kDa), TNF-R1 (55 kDa), FLIPL (50 kDa), and FLIPS (23 kDa) was
examined in PBMC of four different Se´zary patients. For comparison, protein extracts of two T-ALL (CCRF-CEM, Karpas-45) and two CTCL cell lines (MyLa, HH)
were applied to the right and left, respectively. (b) As controls, PBMC of six normal blood donors were also analyzed. In the control blot, protein extracts of a T-
ALL (Karpas-45) and a CTCL cell line (MyLa) were applied to the left. Identical protein amounts (25 mg per lane) had been loaded in each lane and consistent
blotting was confirmed by Ponceau red staining and detection of GAPDH. (c) c-FLIP expression is demonstrated by immunohistology in biopsies of five different
MF patients (bar¼ 0.1 mm).
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expression. Proteasome inhibition may thus result in c-FLIP
downregulation and may thereby sensitize CTCL cells for
endogeneous or exogeneously supplied TRAIL. Synergistic
effects of TRAIL receptor agonists and bortezomib have
already been reported for lymphoma cells (Georgakis et al.,
2005).
Moreover, IFN-a and IFN-b were shown to induce
apoptosis in myeloma and lymphoma cells by upregulation
of TRAIL (Gomez-Benito et al., 2005; Oehadian et al., 2005;
Yanase et al., 2005). Particularly, IFN-a is used in CTCL
therapy (Olsen, 2003). With the present data, it may be
suggestive to try to improve IFN-a efficacy by parallel
application of agents that increase TRAIL sensitivity of CTCL
cells.
In summary, unraveling the basis of apoptosis resistance of
CTCL cells exposes several features possibly related to the
clinical situation and to current therapeutic options for CTCL.
This may emphasize the implications of apoptosis resistance
for cutaneous lymphoma. The better understanding of the
apoptosis pathways in CTCL may finally help to adapt and
improve its therapy.
MATERIALS AND METHODS
Patients
Patients with investigated PBMC protein extracts had stage IVB
Se´zary syndrome (two male, two female; mean age: 77 years).
Tumor load was ranged between 7.3 106 and 19.3 106/ml. All
patients had received pretreatment with psoralenþUVA treatment
and IFN-a as well as additional individual therapies (methotrexate,
chlorambucil/prednisolone, extracorporeal photochemotherapy, or
leukapheresis). The 35 patients, from whom biopsies were investi-
gated by immunohistology for c-FLIP expression, had clinically and
histologically confirmed MF (19, stage IB; 11, stage IIB; 5, stage III;
females: 25%; median age: 64 years). This study was approved by
the Charite´ and the study was conducted according to the
Declaration of Helsinki Principles.
Cell culture and quantification of apoptosis
Four CTCL cell lines have been used: MyLa derived from a plaque
biopsy of a patient with MF (Kaltoft et al., 1992); SeAx (Kaltoft et al.,
1987) and HuT-78 (Gootenberg et al., 1981) derived from PBMCs of
patients with Se´zary syndrome; HH derived from peripheral blood of
a patient with aggressive CTCL (Starkebaum et al., 1991) (ATCC,
Manassas, VA; CRL2105). For comparison, four T-ALL cell lines were
used: CCRF-CEM (Foley et al., 1965), MOLT-4 (Minowada et al.,
1972), Karpas-45 (Smith et al., 1973), and Jurkat (Schneider et al.,
1977). As controls for decoy-receptor expression, colon carcinoma
cells SW480 (Fogh et al., 1977) and cervix carcinoma cells HeLa
(Scherer et al., 1953) were used.
Cells were cultivated at 371C with 5% CO2 in a fully humidified
atmosphere. Six lymphoma cell lines and the two controls were
grown in RPMI 1,640 medium, supplemented with L-glutamine
(Biochrom, Berlin, Germany); MyLa and SeAx were grown in DMEM
containing 4.5 g/l glucose, 25 mM N-2-hydroxyethylpiperazine-N0-2-
ethanesulfonic and glutamax (Invitrogen, Karlsruhe, Germany). Both
growth media were in addition supplemented with 10% fetal calf
serum and antibiotics (Biochrom). SeAx cells have been originally
cultivated in the presence of IL-2 as reported previously (Kaltoft
et al., 1987) but were cultivated here without IL-2 for reasons of
better comparison. An IL-2-independent cell line was obtained after
short-term selection for 4 weeks.
For induction of apoptosis, three death receptor agonists were
used: (1) KillerTRAIL (soluble, human, recombinant; Alexis, Gruen-
berg, Germany ALX-201-073-C020; 20 ng/ml); (2) TNF-a (Sigma,
Taufkirchen, Germany; 10 ng/ml), and (3) anti-CD95 antibody CH-
11 (IgM mouse; Beckman Coulter, Krefeld, Germany; 100 ng/ml).
Cells (2 105/well) were seeded with 2 ml growth medium in six-
well plates. After 24 hours, growth medium was changed and death
agonists were applied for another 16 hours. Thereafter, apoptosis
assays or protein extractions for analysis of the caspase cascade were
performed.
Apoptosis was quantified with a cell-death detection ELISA
(Roche Diagnostics, Mannheim, Germany), which detects mono-
and oligonucleosomes formed in apoptotic cells. The protocol is
detailed by the supplier and described previously (Eberle et al.,
2003).
Flow cytometry
For determination of surface expression for TRAIL receptors DR4,
DR5, DcR1, and DcR2, cells were harvested from cell culture flasks
by centrifugation at a density of about 1 106 cells/ml, after
supplying fresh growth medium one day before. After washing with
phosphate-buffered saline (PBS), aliquots of 1 106 cells in 100ml
PBS, 1% BSA were incubated for 30 minutes with mAb against
TRAIL-R1/DR4 (Alexis, HS101, 1:100), TRAIL-R2/DR5 (Alexis, clone
HS 201, 1:100), TRAIL-R3/DcR1 (mouse monoclonal IgG, mab6302;
R&D Systems, Minneapolis, MN, 1:100) and against TRAIL-R4/DcR2
(mouse monoclonal IgG, mab633, R&D Systems, 1:100), respec-
tively. An isotypic monoclonal mouse IgG1 antibody (Alexis, clone
MOPC31C, 278-010, 1:100) was used as negative control. After
washing cells two times with PBS, they were incubated for
30 minutes with the secondary phycoerythrin-labeled goat anti-
mouse IgG1 antiserum (Alexis, 211-201-C050; 1:100).
For determination of CD95 surface expression, cells were
harvested as described above. Aliquots of 1 106 cells in 100ml
PBS, 1% BSA were incubated with phycoerythrin-labeled mono-
clonal CD95 antibody (clone DX2; Becton Dickinson, Heidelberg,
Germany; 1:6) and were compared with a labeled isotypic IgG1
monoclonal control antibody (clone MOPC-21, Becton Dickinson;
1:6). After washing with PBS, surface expression of death receptors
was determined with a FACSCalibur flow cytometer (Becton
Dickinson). The mean fluorescence index was calculated using
CellQuest software (Becton Dickinson).
Western blot analysis
Generally one day before protein extraction, cell cultures received
fresh growth medium. Cells were harvested at a density of about
1 106 cells/ml. Detailed protocols for protein extraction and
Western blot analysis were described in more detail previously
(Eberle et al., 2003). The following antibodies were used: TRAIL-R1/
DR4 (rabbit polyclonal IgG, ab8414; Acris Antibodies, Hiddenhau-
sen, Germany, 1:500); TRAIL-R2/DR5 (rabbit polyclonal IgG,
ab8416, Acris Antibodies, 1:500); TNF-R1 (mouse monoclonal
IgG, H5, sc-8436; Santa Cruz, Heidelberg, Germany, 1:200);
caspase-8 (mouse monoclonal IgG, 1C12; Cell Signaling, Danvers,
1:1,000); caspase-10 (mouse monoclonal IgG, 4C1; MBL Interna-
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tional, Watertown, MA, 1:1,000); caspase-9 (rabbit polyclonal IgG;
Cell Signaling, 1:1,000); caspase-3 cleavage products (rabbit
polyclonal IgG, Asp175; Cell Signaling, 1:1,000); procaspase-3
(rabbit polyclonal IgG; Cell Signaling, 1:1,000); FADD (rabbit
polyclonal IgG; Cell Signaling, 1:1,000); c-FLIP (mouse monoclonal
IgG, G-11, sc-5276, Santa Cruz, 1:200); Bid (rabbit, polyclonal
IgG; Cell Signaling, 1:1,000); Bax (rabbit polyclonal IgG, N-20, sc-
493; Santa Cruz, 1:200); Bcl-2 (mouse monoclonal IgG, sc-509;
Santa Cruz, 1:200); Bcl-xL (rabbit polyclonal IgG, S-18, sc-634;
Santa Cruz, 1:200); survivin (mouse monoclonal IgG, D-8,
sc-17779; Santa Cruz, 1:200); X-linked inhibitor of apoptosis (rabbit
polyclonal IgG; Cell Signaling, 1:1,000); a-tubulin (rabbit polyclonal
IgG; Cell Signaling, 1:1,000); glyceraldehyde-3-phosphate dehydro-
genase (mouse monoclonal IgG, 6C5, sc-32233; Santa Cruz, 1:200);
b-actin (mouse monoclonal IgG, A5541; Sigma-Aldrich, Seelze,
Germany, 1:5,000).
Two secondary horseradish peroxidase-labeled antibodies were
used: horseradish peroxidase-labeled goat anti-rabbit Ig and horse-
radish peroxidase-labeled goat anti-mouse Ig (both from Dako
Cytomation, Hamburg, Germany, 1:5,000).
Preparation of PBMCs of Se´zary patients
Peripheral white blood cells of Se´zary patients were harvested by
leukaphoresis, controls derived from normal blood donors. Cells
were washed twice with PBS/0.1% BSA, including heparin in the first
washing buffer to prevent coagulation. Each time, the cells were
centrifuged for 5 minutes at 300 g. The cells were cryopreserved at
1401C in 90% fetal calf serum/10% DMSO. For retrieval, they
were thawed quickly and washed twice in protein-free PBS. For
protein analysis, they were then lysed in the respective buffer. The
content of tumor cells in these preparations was 60–80% as assessed
from the total cell yield compared to normal controls, scatter
analysis and, in some cases, fraction of the cells with the T-cell
receptor Vb-family type of the tumor cells both determined by flow
cytometry and differential blood cell diagnostics.
Immunohistology
Paraffin-embedded specimens were drawn from the files of the
Department of Dermatology and Allergy, Charite´. To unmask
antigen epitopes, sections were pretreated by high-pressure cooking
(20 mM EDTA buffer, pH 8.0). Expression of c-FLIP was detected by
the murine monoclonal antibody G-11 (Santa Cruz, sc-5276, 1:25).
Immunohistological staining was performed as described previously
(Cordell et al., 1984) and appropriate positive and negative controls
were included. Tumor cells were identified by gyrated nuclei and
CD3 staining.
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